Medicon Valley Alliance together with member company Miltenyi Biotec have the pleasure to invite you to the 12th meeting of the Medicon Valley Alliance Oncology Network on the 16th of March, 2022. Immuno-oncology is sometimes referred to as the fifth pillar of cancer treatment, alongside surgery, radiotherapy, chemotherapy and precision therapy. The activation and utilization of the immune system to treat cancer has been successful for some types of cancers, but the success rate varies between different variants. As we continuously learn from current therapies, new ones are emerging. In this MVA Oncology network meeting we would like to invite you to a discussion and interaction on current immuno-oncology developments in the Medicon Valley region. In the meeting we will hear from experts in the immuno-oncology field from academia and research to innovative companies and more established ones.
Date: 16th of March, 2022
Time: 14.30 – 18.00
Venue: Auditorium, Arne Jacobsens Alle 13, 2300 Ørestad City, Copenhagen
Host and moderator: Miltenyi Biotec
PROGRAM:
| 14.30 – 15.00 | Registration and arrival |
| 15.00 – 15.10 | Welcome and introduction Anette Steenberg, CEO, Medicon Valley Alliance & Thomas Kjær Mogensen, Country Manager Nordic & Baltics, Miltenyi Biotec |
| 15.10 – 15.15 | IP in Immuno-Oncology Jens Viktor Nørgaard, Partner, Head of Biotechnology & Plant Sciences, European Patent Attorney, Høiberg |
| 15.15 – 15.30 | Immuno-oncology: Spatial omics as a tool for target identification Sara Ek, Professor, Department of Immunotechnology, Lund University |
| 15.30 – 15.45 | Adoptive T-Cell Immunotherapy for Cancer Özcan Met, Associate Professor & Head of Cell Therapy Unit, National Center for Cancer Immune Therapy, Herlev University Hospital |
| 15.45 – 16.00 | Developing In Vivo Immune Cell Reprogramming technologies to Reinstate Anti-Cancer Immunity Fabio Rosa, Co-founder, Asgard Therapeutics |
| 16.00 – 16.20 | Break |
| 16.20 – 16.35 | Neo-X-prime™ a novel myeloid engager for cancer therapy, Peter Ellmark, CSO, Alligator Bioscience |
| 16.35 – 16.50 | Ex-vivo wake-up call for the T-cells to combat cancer – ‘Novoleucel’ – a TIL cell-therapy product with transformative potential Ulrik Cordes, CEO, C-bio |
| 16.50 – 17.15 | Q&A and discussion |
| 17.15 | Networking and refreshments |
Deadline for registration is 11th of March.
For more information please contact Sofia Norås sn@mva.org
The network
MVA Oncology Network is a professional and social network for professors, PIs and corporate level executives from the regional oncology eco-system. The network focuses on best practice, experience and current challenges for public-private collaboration and the commercialization of oncology related R&D in the Medicon Valley region.
Joining the network is free of charge and is limited to Medicon Valley Alliance members only. However, non-member organizations and companies are welcome to attend one network event to evaluate if joining the network is relevant. If so, becoming a member of Medicon Valley Alliance will automatically allow you to join the oncology network.
| Host and sponsor | Sponsor |
 |
 |
| In collaboration with | |
 |
 |